Search results
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Zacks· 1 day agoFree Report) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. A quarter ago, it was expected that this clinical-stage biotech company that develops ...
Brokers Offer Predictions for Apellis Pharmaceuticals, Inc.’s FY2026 Earnings (NASDAQ:APLS)
ETF DAILY NEWS· 6 hours agoWedbush analyst L. Chico now forecasts that the company will post earnings per share of $4.29 for the year, down from their prior forecast of $4.50. Wedbush currently has a “Neutral” rating ...
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Motley Fool via Yahoo Finance· 2 days agos a fair price to pay for the CF drugs that it's already marketing. In other words, investors who...
Analyzing BioRestorative Therapies (BRTX) and Its Rivals
ETF DAILY NEWS· 6 days agoBioRestorative Therapies (NASDAQ:BRTX – Get Free Report) is one of 20 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare ...
Brainstorm Cell Therapeutics (NASDAQ:BCLI) versus Windtree Therapeutics (NASDAQ:WINT) Head to Head...
ETF DAILY NEWS· 6 days agoWindtree Therapeutics (NASDAQ:WINT – Get Free Report) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) are both small-cap medical companies, but which is the ...
Sanofi's New Cancer Drug Could Help Deliver a Big Payday
Motley Fool via Yahoo Finance· 2 days agoSanofi expects its 2024 earnings per share to pull back a little before rebounding in 2025. The...
Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoAgenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript May 7, 2024 Agenus Inc. beats earnings...
bluebird bio reports first commercial gene therapy use By Investing.com
Investing.com· 4 days agoThis development marks a major step in making the treatment accessible to patients with a history of...
Ballard Power shares target cut by Piper Sandler on weak financials By Investing.com
Investing.com· 2 days agoThe firm decreased the price target for Ballard Power to $2.20 from the previous $2.30 while...
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
InvestorPlace· 6 days agoThis excellent opportunity that biotech stocks present can provide investors with potentially...
